COX CARRIE SMITH Form 5 February 15, 2002

FORM 5				OMB APPROVA
[] Check box if no] Section 16. Form may continue. See		OMB Number: 32 Expires: December 3 Estimated average b hours per response.		
[] Form 3 Holdings F	Reported			
[] Form 4 Transaction	ons Reported			
	UNITEI	O STATES SECURITIES AND EXC Washington, D.C. 2054		COMMISSION
	t to Section 16(a) of	EMENT OF CHANGES IN BENEFIC the Securities Exchange Ac 1935 or Section 30(f) of t	ct of 1	934, Section 17(a) of
1. Name and Address of				Issuer Name and Ticke
	Carrie	Smith		Pharmacia C
	(First)			I.R.S. Identification Number of Reporting Person, if an entity
1	100 Route 206 North			(Voluntary)
	(Street)			
Peapack,	NJ	07977		
(City) (S	State)	(Zip)		
	Reporting Person(s) to	 D Issuer		
Director				

	X Officer (give title below)		Othe	er (specify below)				
Exe	ecutive Vice President							
7.	Individual or Joint/Grou (check Applicable L	p Repor						
	X Form filed by One Repo	rting P	erson					
	Form filed by More th							
	Table I - Non-Derivative S Title of Security (Instr. 3)			2. Trans- action Date (Month/	3. Tr ac Cc			
				Day/ Year)				Amount
Cor	nmon (1)			04/16/2001		А	2	25,000
Cor	nmon							
5.	Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6.	Ownership Form: Direct or Indirect ((Instr. 4)		7.	Nature of Indirect Beneficial Ownership (Instr. 4)	_	
	32 , 669 (2)		D					
	2,043 (3)		I			Savings Plans	- S	
							-	

*If the form is filed by more than one reporting person, see Instruction $4\left(b\right)\left(v\right)$.

(Over) SEC 2270 (3-99)

Page 1 of 3

FORM 5 (continued)

Cox, Carrie Smith - December 2001

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		4. Transac- tion Code (Instr. 8)	Derivati Securiti Acquired or Dispo (D)	. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and	
				(A)	(D)	Dat Exe abl
Option (right to buy)						(4
Option (right to buy)	\$49.10	04/02/2001		2,036		(5
Option (right to buy)	\$57.84					(6
Option (right to buy)	\$51.59					(4
Option (right to buy)						(6
Option (right to buy)						(6
Option (right to buy)						(6
Option (right to buy)	\$28.99					(6
Performance Share Units	1-for-1					(7

7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Securities	10. Ownership of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	of Indir Benefici
Title	Amount or Number of Shares			
Common	147,964	 	D	
Common	2,036	150,000	D	
	4,556	4,556	D	
Common	125,000	125,000	D	
Common	119,000	 119,000	D	
Common	119,000	119,000	D	
	89,250	89,250	D	
	67 , 709	 67,709	D	
Common	100,000	 100,000	D	

Explanation of Responses:

See attached statement

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Don W. Schmitz 2/14/2002

** Signature of Reporting Person Date
Don W. Schmitz, attorney-in-fact for
Carrie Smith Cox

Page 2 SEC 2270 (3-99)

Page 2 of 3

Pharmacia Corporation PHA

Form 5 - December 2001

Cox, Carrie Smith 100 Route 206 North Peapack, NJ 07977

Explanation of responses:

- (1) Restricted Shares
- (2) Includes 25,000 Restricted Shares
- (3) Includes 622 shares acquired in the Pharamacia & Upjohn Savings Plan and Pharmacia Savings Plus since last reported to the SEC.
- (4) Option becomes exercisable for one-third of the shares on the first, second and third anniversary of the grant date.
- (5) Option exercisable on 4/02/2004
- (6) Option is currently exercisable.
- (7) Performance share units will be earned on the earlier of 12/31/04 (unless employment terminates) or the date of change-in-control with the ultimate payout in the range of 0% to 125% of the number of units granted based upon the Company's relative total shareholder return compared to peer companies and absolute total shareholder return over the performance period.

Page 3 of 3